Chemomab Therapeutics (Chemomab Therapeutics) Net Cash per Share : $0.79 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Chemomab Therapeutics's Net Cash per Share for the quarter that ended in Mar. 2024 was $0.79.

The historical rank and industry rank for Chemomab Therapeutics's Net Cash per Share or its related term are showing as below:

CMMB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.5 Med: 1.01 Max: 5.93
Current: 1.29

During the past 4 years, the highest Price-to-Net-Cash Ratio of Chemomab Therapeutics was 5.93. The lowest was 0.50. And the median was 1.01.

CMMB's Price-to-Net-Cash is ranked better than
83.95% of 866 companies
in the Biotechnology industry
Industry Median: 3.955 vs CMMB: 1.29

Chemomab Therapeutics Net Cash per Share Historical Data

The historical data trend for Chemomab Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Net Cash per Share Chart

Chemomab Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

0.91

5.11

2.99

1.03

Chemomab Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
Net Cash per Share	Get a 7-Day Free Trial											2.99	2.32	1.67	1.03	0.79

Competitive Comparison of Chemomab Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Chemomab Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Price-to-Net-Cash falls into.

Chemomab Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Chemomab Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(19.784	-	5.154	-	0)	/	14.2047
=	1.03

Chemomab Therapeutics's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

	Net Cash per Share (Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(15.877	-	4.678	-	0)	/	14.219
=	0.79

Chemomab Therapeutics (NAS:CMMB) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Chemomab Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemomab Therapeutics (Chemomab Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

2QV0:Germany

Address

Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Website

https://www.chemomab.com

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Executives

Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor	director, 10 percent owner, officer: Chief Executive Officer	15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen	director	C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel	officer: Chief Medical Officer	672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley	director	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles	director	5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin	officer: Executive VP, CFO & COO	2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost	director, officer: Chief Executive Officer	ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish	director	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel	10 percent owner	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal	officer: Chief Financial Officer	16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon	officer: Chief Medical Officer	12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses	director	C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto	director	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629